{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T22:13:49Z","timestamp":1759529629042},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1097\/wnf.0b013e31828003c1","type":"journal-article","created":{"date-parts":[[2013,3,22]],"date-time":"2013-03-22T22:04:40Z","timestamp":1363989880000},"page":"37-41","source":"Crossref","is-referenced-by-count":24,"title":["Reboxetine Treatment for Autistic Spectrum Disorder of Pediatric Patients With Depressive and Inattentive\/Hyperactive Symptoms"],"prefix":"10.1097","volume":"36","author":[{"given":"Pavel","family":"Golubchik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Sever","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abraham","family":"Weizman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R2-1-20210203","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/BF01531783","article-title":"Aspergers syndrome and recurrent psychosisa case study.","volume":"15","author":"Gillberg","year":"1985","journal-title":"J Autism Dev Disord"},{"key":"R3-1-20210203","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/BF02094180","article-title":"Comorbidity of autistic disorder in children and adolescents.","volume":"1","author":"Ghaziuddin","year":"1992","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"R5-1-20210203","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1192\/bjp.159.5.721","article-title":"Depression in autistic disorder.","volume":"159","author":"Ghaziuddin","year":"1991","journal-title":"Br J Psychiatry"},{"key":"R6-1-20210203","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/BF02408557","article-title":"Infantile autism and affective disorder.","volume":"14","author":"Komoto","year":"1984","journal-title":"J Autism Dev Disord"},{"key":"R7-1-20210203","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1192\/bjp.155.5.692","article-title":". Pervasive developmental disorders and psychoses in adult life.","volume":"155","author":"Clarke","year":"1989","journal-title":"Br J Psychiatry"},{"key":"R8-1-20210203","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1017\/S0033291700053332","article-title":"Aspergers syndrome: a clinical account.","volume":"11","author":"Wing","year":"1981","journal-title":"Psychol Med"},{"key":"R9-1-20210203","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1023\/A:1026036514719","article-title":"Depression in children with autismpervasive developmental disorders: a case-control family history study.","volume":"28","author":"Ghaziuddin","year":"1998","journal-title":"J Autism Dev Disord"},{"key":"R10-1-20210203","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1177\/1362361300004002002","article-title":". The prevalence of anxiety and mood problems among children with autism and Asperger syndrome.","volume":"4","author":"Kim","year":"2000","journal-title":"Autism"},{"key":"R11-1-20210203","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/BF02172140","article-title":"Affective disorders in people with autism: a review of published cases.","volume":"24","author":"Lainhart","year":"1994","journal-title":"J Autism Dev Disord"},{"key":"R12-1-20210203","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1177\/1362361301005003004","article-title":". The phenomenology of depressive illness in people with a learning disability and autism.","volume":"5","author":"Perry","year":"2001","journal-title":"Autism"},{"key":"R13-1-20210203","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1037\/0022-006X.61.3.475","article-title":". Parental perception of emotional expressiveness in children with autism.","volume":"61","author":"Capps","year":"1993","journal-title":"J Consult Clin Psychol"},{"key":"R14-1-20210203","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1007\/s10803-006-0292-x","article-title":". Intellectual ability, self-perceived social competence, and depressive symptomatology in children with high-functioning autistic spectrum disorders.","volume":"37","author":"Vickerstaff","year":"2007","journal-title":"J Autism Dev Disord"},{"key":"R15-1-20210203","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1097\/00004583-199907000-00024","article-title":". Higher-functioning pervasive developmental disorders: rates and patterns of psychotropic drug use.","volume":"38","author":"Martin","year":"1999","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R16-1-20210203","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1089\/cap.1997.7.9","article-title":". Sertraline treatment of transition-associated anxiety and agitation in children with autistic disorder.","volume":"7","author":"Steingard","year":"1997","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R17-1-20210203","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/j.1469-8749.1998.tb15414.x","article-title":"Effects of fluoxetine treatment in young children with idiopathic autism.","volume":"40","author":"DeLong","year":"1998","journal-title":"Dev Med Child Neurol"},{"key":"R18-1-20210203","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.pnpbp.2005.10.002","article-title":"Low-dose venlafaxine in three adolescents and young adults with autistic disorder improves self-injurious behavior and attention deficithyperactivity disorders (ADHD)-like symptoms.","volume":"30","author":"Carminati","year":"2006","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R19-1-20210203","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1177\/088307380001500214","article-title":". Venlafaxine in children, adolescents, and young adults with autism spectrum disorders: an open retrospective clinical report.","volume":"15","author":"Hollander","year":"2000","journal-title":"J Child Neurol"},{"key":"R20-1-20210203","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/archpsyc.62.11.1266","article-title":"Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity.","volume":"62","year":"2005","journal-title":"Arch Gen Psychiatry"},{"key":"R21-1-20210203","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1097\/01.chi.0000231976.28719.2a","article-title":". Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial.","volume":"45","author":"Arnold","year":"2006","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"Suppl 1","key":"R22-1-20210203","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/S0924-977X(97)00417-3","article-title":"Review of the pharmacokinetics and metabolism of reboxetine, a selective noradrenaline reuptake inhibitor.","volume":"7","author":"Dostert","year":"1997","journal-title":"Eur Neuropsychopharmacol"},{"key":"R23-1-20210203","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1124\/dmd.31.1.98","article-title":". Disposition and metabolic fate of atomoxetine hydrochloride: the role of CYP2D6 in human disposition and metabolism.","volume":"31","author":"Sauer","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"R24-1-20210203","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/01.chi.0000155327.30017.8c","article-title":". Six-week open-label reboxetine treatment in children and adolescents with attention-deficithyperactivity disorder.","volume":"44","author":"Ratner","year":"2005","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R25-1-20210203","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1089\/cap.2006.0145","article-title":". Reboxetine maintenance treatment in children with attention-deficithyperactivity disorder: a long-term follow-up study.","volume":"17","author":"Toren","year":"2007","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R26-1-20210203","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00787-008-0705-9","article-title":"Reboxetine versus methylphenidate in treatment of children and adolescents with attention deficit-hyperactivity disorder.","volume":"18","author":"Arabgol","year":"2009","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"R27-1-20210203","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.euroneuro.2007.07.005","article-title":". A meta-analysis of clinical trials comparing reboxetine, a norepinephrine reuptake inhibitor, with selective serotonin reuptake inhibitors for the treatment of major depressive disorder.","volume":"18","author":"Papakostas","year":"2008","journal-title":"Eur Neuropsychopharmacol"},{"key":"R28-1-20210203","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/s10803-006-0147-5","article-title":"Behavioral and emotional problems in young people with pervasive developmental disorders: relative prevalence, effects of subject characteristics, and empirical classification.","volume":"36","author":"Lecavalier","year":"2006","journal-title":"J Autism Dev Disord"},{"key":"R29-1-20210203","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/1362361301005001006","article-title":". The Asperger Syndrome (and high-functioning autism) Diagnostic Interview (ASDI): a preliminary study of a new structured clinical interview.","volume":"5","author":"Gillberg","year":"2001","journal-title":"Autism"},{"key":"R31-1-20210203","first-page":"200","article-title":". Use of the Childrens Depression Rating Scale in an inpatient psychiatric population.","volume":"44","author":"Poznanski","year":"1983","journal-title":"J Clin Psychiatry"},{"key":"R33-1-20210203","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1089\/cap.2007.0066","article-title":". Efficacy and safety of atomoxetine in adolescents with attention-deficithyperactivity disorder and major depression.","volume":"17","author":"Bangs","year":"2007","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R34-1-20210203","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1177\/1362361306073001","article-title":". Atomoxetine treating patients with autistic disorder.","volume":"10","author":"Niederhofer","year":"2006","journal-title":"Autism"},{"key":"R35-1-20210203","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1089\/cap.2006.16.599","article-title":". Open-label atomoxetine for attention-deficit hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders.","volume":"16","author":"Posey","year":"2006","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R36-1-20210203","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1111\/j.1651-2227.2011.02263.x","article-title":"Response to atomoxetine in boys with high-functioning autism spectrum disorders and attention deficithyperactivity disorder.","volume":"100","author":"Zeiner","year":"2011","journal-title":"Acta Paediatr"},{"key":"R38-1-20210203","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.jaac.2012.04.011","article-title":"M, van de Loo-Neus G, Minderaa RB, et al.. A randomized double-blind study of atomoxetine versus placebo for attention-deficithyperactivity disorder symptoms in children with autism spectrum disorder.","volume":"51","year":"2012","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R39-1-20210203","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1177\/1087054708320404","article-title":"Comparative study of children with ADHD only, autism spectrum disorder ADHD, and chronic multiple tic disorder ADHD.","volume":"12","author":"Gadow","year":"2009","journal-title":"J Atten Disord"}],"container-title":["Clinical Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/WNF.0b013e31828003c1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T07:15:15Z","timestamp":1620976515000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002826-201303000-00001"}},"subtitle":["An Open-Label Trial"],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/wnf.0b013e31828003c1","relation":{},"ISSN":["0362-5664"],"issn-type":[{"value":"0362-5664","type":"print"}],"subject":[],"published":{"date-parts":[[2013,3]]}}}